These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group. Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342 [TBL] [Abstract][Full Text] [Related]
29. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Kaakkola S Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464 [TBL] [Abstract][Full Text] [Related]
31. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis. Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736 [TBL] [Abstract][Full Text] [Related]
32. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768 [TBL] [Abstract][Full Text] [Related]
33. European Union directives on medicinal products found to be seriously defective. Griffin JP Adverse Drug React Toxicol Rev; 1999 Mar; 18(1):3-4. PubMed ID: 10401519 [No Abstract] [Full Text] [Related]
34. The rise and fall of tolcapone. Colosimo C J Neurol; 1999 Oct; 246(10):880-2. PubMed ID: 10552233 [No Abstract] [Full Text] [Related]
35. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Davis TL; Roznoski M; Burns RS Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456 [TBL] [Abstract][Full Text] [Related]
36. Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease. Unger MM; Reese JP; Oertel WH; Eggert KM Eur Neurol; 2008; 60(3):122-6. PubMed ID: 18628629 [TBL] [Abstract][Full Text] [Related]